Table 1.

Main results of pivotal clinical trials with direct oral anticoagulants.^a

	RE-LY (CHA2DS2 2.1)	ROCKET-AF (CHA2DS2 3.5)	ARISTOTLE (CHA2DS2 2.1)	ENGAGE AF-TIMI 48 (CHA2DS2 2.8)
	RR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Stroke or systemic embolism	D150–W: 0.66 (0.53–0.82)	R–W: 0.88 (0.75–1.03)b	A–W: 0.79 (0.66–0.95)	E60–W: 0.87 (0.73–1.04)b,c
	D110–W: 0.91 (0.74–1.11)
Ischemic stroke	D150–W: 0.76 (0.60–0.98)	R–W: 0.94 (0.75–1.17)	A–W: 0.92 (0.74–1.13)	E60–W: 1.00 (0.83–1.19)
	D110–W: 1.11 (0.89–1.40)
Hemorrhagic stroke	D150–W: 0.26 (0.14–0.49)	R–W: 0.59 (0.37–0.93)	A–W: 0.51 (0.35–0.75)	E60–W: 0.54 (0.38–0.77)
	D110–W: 0.31 (0.17–0.56)
Major bleeding	D150–W: 0.93 (0.81–1.07)	R–W: 1.04 (0.90–1.20)	A–W: 0.69 (0.60–0.80)	E60–W: 0.80 (0.71–0.91)
	D110–W: 0.80 (0.69–0.93)
Intracranial bleeding	D150–W: 0.40 (0.27–0.60)	R–W: 0.67 (0.47–0.93)	A–W: 0.42 (0.30–0.58)	E60–W: 0.47 (0.34–0.63)
	D110–W: 0.31 (0.20–0.47)
Cardiovascular death	D150–W: 0.85 (0.72–0.99)	R–W: 0.89 (0.73–1.10)	A–W: 0.89 (0.76–1.04)	E60–W: 0.86 (0.77–0.97)
	D110–W: 0.90 (0.77–1.06)

^aData retrieved from Connolly et al.,²⁹ Patel et al.,³⁰ Granger et al.,³¹ Giugliano et al.³²;

^bIntention-to-treat analysis;

^cA 97.5% confidence interval was used.

A, apixaban; D110, dabigatran 110 mg; D150, dabigatran 150 mg; E60, edoxaban 60 mg; R, rivaroxaban; RR, relative risk; W, warfarin.